SRPT
Closed
Sarepta Therapeutics Inc
17.71
+0.61 (+3.57%)
Last Update: 01 Jul 2025 23:23:00
Yesterday: 17.1
Day's Range: 16.88 - 18.62
Send
sign up or login to leave a comment!
When Written:
140.38
Sarepta Therapeutics Inc is a biopharmaceutical company focused on the development of treatments for rare, genetic diseases. The company was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Sarepta's primary focus is on developing treatments for Duchenne muscular dystrophy (DMD), a genetic disorder that causes progressive muscle degeneration and weakness. The company's lead product, Exondys 51 (eteplirsen), is an RNA-targeted therapy that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of DMD in patients with a specific genetic mutation.
Sarepta is also developing other RNA-targeted therapies for DMD, including golodirsen and casimersen, which are currently under review by the FDA. In addition, the company is working on treatments for other rare diseases, including limb-girdle muscular dystrophy and Pompe disease.
Sarepta has partnerships with other biopharmaceutical companies, including Roche and Genethon, to develop treatments for rare diseases. The company has received funding from government agencies, including the National Institute of Neurological Disorders and Stroke and the Department of Defense, to support its research and development efforts.
As of 2021, Sarepta has a market capitalization of over $9 billion and employs over 1,000 people worldwide.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Sarepta's primary focus is on developing treatments for Duchenne muscular dystrophy (DMD), a genetic disorder that causes progressive muscle degeneration and weakness. The company's lead product, Exondys 51 (eteplirsen), is an RNA-targeted therapy that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of DMD in patients with a specific genetic mutation.
Sarepta is also developing other RNA-targeted therapies for DMD, including golodirsen and casimersen, which are currently under review by the FDA. In addition, the company is working on treatments for other rare diseases, including limb-girdle muscular dystrophy and Pompe disease.
Sarepta has partnerships with other biopharmaceutical companies, including Roche and Genethon, to develop treatments for rare diseases. The company has received funding from government agencies, including the National Institute of Neurological Disorders and Stroke and the Department of Defense, to support its research and development efforts.
As of 2021, Sarepta has a market capitalization of over $9 billion and employs over 1,000 people worldwide.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!